Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, 610 University Ave, Ste 3-920, Toronto, ON M5G 2M9, Canada.
AJR Am J Roentgenol. 2023 Jun;220(6):852-861. doi: 10.2214/AJR.22.28665. Epub 2023 Feb 1.
The purpose of this article is to review clinical application of the Prostate Imaging for Recurrence Reporting (PI-RR) system. This system, released in 2021, represents international consensus-based guidelines for the acquisition, interpretation, and reporting of multiparametric MRI performed to detect locally recurrent prostate cancer after radiation therapy or radical prostatectomy. The system reduces variability through use of a standardized and structured reporting approach whereby the overall level of suspicion of recurrence is classified on a 5-point scale. The overall suspicion score is derived from 5-point scales for assessing DWI and dynamic contrast-enhanced (DCE) imaging. Separate scales for both DWI and DCE imaging are provided for evaluation after radiation therapy and after radical prostatectomy. These scales account for the relation between detected abnormalities and the location of the primary tumor on pretreatment imaging. T2-weighted imaging is also assessed on a 5-point scale and is useful for anatomic imaging but does not influence the overall score. Initial retrospective studies have shown promising results with respect to the reproducibility and accuracy of PI-RR in detecting locally recurrent tumor.
本文旨在回顾前列腺影像报告和数据系统（PI-RADS）在临床中的应用。该系统于 2021 年发布，代表了针对放射治疗或根治性前列腺切除术后检测局部复发性前列腺癌的多参数 MRI 采集、解读和报告的国际共识指南。该系统通过使用标准化和结构化报告方法来减少变异性，从而将复发的总体可疑程度分类为 5 分制。总体可疑评分源自用于评估弥散加权成像（DWI）和动态对比增强（DCE）成像的 5 分制。提供了分别用于放射治疗后和根治性前列腺切除术后评估的 DWI 和 DCE 成像的单独评分。这些评分考虑了在治疗前成像上检测到的异常与原发性肿瘤位置之间的关系。T2 加权成像也采用 5 分制进行评估，对于解剖成像很有用，但不会影响总体评分。初步回顾性研究表明，PI-RADS 在检测局部复发性肿瘤方面具有良好的可重复性和准确性。
